BTMD
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.
biote Corp. (BTMD) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B (3.2) | C (2.3) | C+ (2.8) | D+ (1.7) | C+ (2.6) | C+ (2.5) |
| 2026-11-10 | B (3.4) | C (2.2) | C+ (2.8) | D+ (1.6) | C+ (2.6) | C+ (2.5) |
| 2026-11-03 | B (3.3) | C- (2.1) | B- (2.9) | D- (1.0) | C+ (2.7) | C (2.4) |
| 2026-10-27 | B (3.3) | C- (2.1) | B- (2.9) | D- (1.0) | C+ (2.6) | C (2.4) |
| 2026-10-20 | B (3.3) | C- (2.1) | B- (2.9) | D- (1.0) | C+ (2.6) | C (2.4) |